We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Options First-in-Class Antiviral Based on Phase 2 Data
Novartis Options First-in-Class Antiviral Based on Phase 2 Data
After flopping a phase 3 trial in hospitalized COVID-19 patients, Molecular Partners’ antiviral ensovibep has scored in a new phase 2 study, reducing viral load and cutting the risk of hospitalization or death by 78 percent in patients with mild-to-moderate disease.